Concepts (216)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Venous Thromboembolism | 20 | 2022 | 365 | 6.580 |
Why?
|
| Anticoagulants | 19 | 2022 | 785 | 3.710 |
Why?
|
| Anemia, Pernicious | 6 | 2021 | 12 | 3.590 |
Why?
|
| Vitamin B 12 Deficiency | 7 | 2021 | 53 | 3.230 |
Why?
|
| Heparin, Low-Molecular-Weight | 7 | 2020 | 62 | 2.840 |
Why?
|
| Thrombosis | 7 | 2022 | 747 | 1.770 |
Why?
|
| Purpura, Thrombocytopenic | 2 | 2018 | 17 | 1.110 |
Why?
|
| Red-Cell Aplasia, Pure | 2 | 2018 | 50 | 1.080 |
Why?
|
| Fibrinolytic Agents | 3 | 2014 | 302 | 1.050 |
Why?
|
| Bone Marrow Diseases | 2 | 2018 | 187 | 1.010 |
Why?
|
| Vitamin B 12 | 4 | 2021 | 75 | 0.910 |
Why?
|
| Neoplasms | 14 | 2022 | 15849 | 0.890 |
Why?
|
| Thymoma | 2 | 2018 | 253 | 0.840 |
Why?
|
| Pancreatic Neoplasms | 5 | 2022 | 5233 | 0.790 |
Why?
|
| Outpatients | 2 | 2016 | 470 | 0.790 |
Why?
|
| Thymus Neoplasms | 2 | 2018 | 420 | 0.750 |
Why?
|
| Hemorrhage | 3 | 2016 | 742 | 0.730 |
Why?
|
| Gastritis, Atrophic | 2 | 2017 | 66 | 0.690 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2020 | 137 | 0.670 |
Why?
|
| Heparin | 4 | 2017 | 346 | 0.670 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2020 | 212 | 0.660 |
Why?
|
| Primary Prevention | 1 | 2020 | 240 | 0.620 |
Why?
|
| Lead | 1 | 2018 | 44 | 0.600 |
Why?
|
| Folic Acid Deficiency | 1 | 2018 | 55 | 0.600 |
Why?
|
| Anemia | 3 | 2018 | 730 | 0.580 |
Why?
|
| Autoimmune Diseases | 3 | 2017 | 425 | 0.570 |
Why?
|
| Disseminated Intravascular Coagulation | 2 | 2015 | 100 | 0.560 |
Why?
|
| Pyridones | 2 | 2019 | 361 | 0.540 |
Why?
|
| Anemia, Aplastic | 1 | 2018 | 233 | 0.530 |
Why?
|
| Antifibrinolytic Agents | 1 | 2015 | 38 | 0.490 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2020 | 853 | 0.490 |
Why?
|
| Ambulatory Care | 2 | 2021 | 604 | 0.490 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 1 | 2015 | 64 | 0.480 |
Why?
|
| Alcohol Drinking | 1 | 2018 | 592 | 0.470 |
Why?
|
| Reticulocytosis | 1 | 2014 | 1 | 0.470 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2014 | 351 | 0.470 |
Why?
|
| Blood Coagulation | 1 | 2015 | 168 | 0.470 |
Why?
|
| Anemia, Macrocytic | 1 | 2014 | 12 | 0.460 |
Why?
|
| Randomized Controlled Trials as Topic | 6 | 2022 | 2669 | 0.460 |
Why?
|
| Hemoglobinuria, Paroxysmal | 1 | 2014 | 37 | 0.460 |
Why?
|
| Humans | 56 | 2022 | 270757 | 0.450 |
Why?
|
| Hemolysis | 1 | 2014 | 127 | 0.450 |
Why?
|
| Afibrinogenemia | 1 | 2013 | 12 | 0.440 |
Why?
|
| Pregnancy Complications, Hematologic | 1 | 2013 | 38 | 0.430 |
Why?
|
| Leukemia, Erythroblastic, Acute | 1 | 2014 | 123 | 0.430 |
Why?
|
| Clonal Evolution | 1 | 2014 | 251 | 0.410 |
Why?
|
| Fibrinogen | 1 | 2013 | 213 | 0.400 |
Why?
|
| Lung Neoplasms | 3 | 2020 | 11761 | 0.400 |
Why?
|
| Blood Transfusion | 1 | 2015 | 579 | 0.390 |
Why?
|
| Thalidomide | 1 | 2015 | 600 | 0.390 |
Why?
|
| Fanconi Anemia | 1 | 2011 | 90 | 0.370 |
Why?
|
| Leukocytosis | 1 | 2010 | 115 | 0.360 |
Why?
|
| Autoantibodies | 3 | 2019 | 598 | 0.360 |
Why?
|
| Pyrazoles | 2 | 2019 | 1542 | 0.350 |
Why?
|
| Thrombectomy | 1 | 2010 | 166 | 0.320 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2015 | 1268 | 0.300 |
Why?
|
| Adenocarcinoma | 3 | 2021 | 7936 | 0.290 |
Why?
|
| Venous Thrombosis | 1 | 2010 | 378 | 0.270 |
Why?
|
| Thrombocytopenia | 3 | 2018 | 871 | 0.260 |
Why?
|
| Intracranial Hemorrhages | 2 | 2017 | 116 | 0.260 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2020 | 4956 | 0.240 |
Why?
|
| Sclerosis | 1 | 2003 | 82 | 0.230 |
Why?
|
| Multiple Myeloma | 1 | 2015 | 2321 | 0.220 |
Why?
|
| Myeloproliferative Disorders | 1 | 2010 | 881 | 0.210 |
Why?
|
| Bone Marrow Neoplasms | 1 | 2003 | 128 | 0.200 |
Why?
|
| Hematologic Tests | 2 | 2019 | 84 | 0.200 |
Why?
|
| Histiocytes | 1 | 2002 | 95 | 0.200 |
Why?
|
| Central Venous Catheters | 1 | 2022 | 100 | 0.190 |
Why?
|
| Carcinoid Tumor | 1 | 2003 | 281 | 0.190 |
Why?
|
| Catheterization, Peripheral | 1 | 2022 | 159 | 0.180 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2014 | 3145 | 0.180 |
Why?
|
| Calcinosis | 1 | 2003 | 432 | 0.180 |
Why?
|
| Antineoplastic Agents | 2 | 2020 | 14678 | 0.170 |
Why?
|
| Mediastinal Neoplasms | 1 | 2003 | 429 | 0.170 |
Why?
|
| Diagnosis, Differential | 6 | 2015 | 4881 | 0.170 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2018 | 6982 | 0.170 |
Why?
|
| Dabigatran | 1 | 2019 | 27 | 0.170 |
Why?
|
| Catheterization, Central Venous | 1 | 2022 | 365 | 0.170 |
Why?
|
| Rivaroxaban | 1 | 2019 | 58 | 0.160 |
Why?
|
| Nutrition Disorders | 1 | 2018 | 52 | 0.160 |
Why?
|
| Female | 17 | 2020 | 148398 | 0.160 |
Why?
|
| Prednisolone | 1 | 2018 | 133 | 0.150 |
Why?
|
| Anemia, Hemolytic | 1 | 2018 | 54 | 0.150 |
Why?
|
| Diaphragm | 1 | 1999 | 187 | 0.150 |
Why?
|
| Platelet Factor 4 | 1 | 2017 | 37 | 0.150 |
Why?
|
| Copper | 1 | 2018 | 166 | 0.140 |
Why?
|
| Methemoglobinemia | 1 | 2017 | 17 | 0.140 |
Why?
|
| Glucosephosphate Dehydrogenase Deficiency | 1 | 2017 | 14 | 0.140 |
Why?
|
| Antilymphocyte Serum | 1 | 2018 | 237 | 0.140 |
Why?
|
| Risk Factors | 4 | 2022 | 17819 | 0.140 |
Why?
|
| Urate Oxidase | 1 | 2017 | 43 | 0.140 |
Why?
|
| Spinal Cord Injuries | 2 | 2004 | 349 | 0.140 |
Why?
|
| Cyclosporine | 1 | 2018 | 295 | 0.140 |
Why?
|
| Lymphoma, B-Cell | 1 | 2003 | 935 | 0.140 |
Why?
|
| Incidence | 2 | 2017 | 5838 | 0.140 |
Why?
|
| Male | 16 | 2018 | 128346 | 0.140 |
Why?
|
| Gout Suppressants | 1 | 2017 | 73 | 0.130 |
Why?
|
| Breast Neoplasms | 1 | 2020 | 16186 | 0.130 |
Why?
|
| Head and Neck Neoplasms | 1 | 2011 | 4124 | 0.130 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2002 | 1068 | 0.130 |
Why?
|
| Estrogen Receptor alpha | 1 | 2020 | 744 | 0.130 |
Why?
|
| Methylmalonic Acid | 1 | 2015 | 17 | 0.130 |
Why?
|
| Risk | 2 | 2017 | 1914 | 0.120 |
Why?
|
| Administration, Oral | 1 | 2019 | 1617 | 0.120 |
Why?
|
| Prednisone | 1 | 2018 | 1039 | 0.120 |
Why?
|
| Thiazoles | 1 | 2019 | 729 | 0.120 |
Why?
|
| Global Health | 1 | 2020 | 693 | 0.120 |
Why?
|
| Drug Therapy, Combination | 1 | 2020 | 2364 | 0.120 |
Why?
|
| Thrombolytic Therapy | 1 | 2016 | 258 | 0.120 |
Why?
|
| Receptors, Progesterone | 1 | 2020 | 1645 | 0.120 |
Why?
|
| Antibodies | 1 | 2017 | 835 | 0.120 |
Why?
|
| Prostatic Neoplasms | 2 | 2018 | 5990 | 0.110 |
Why?
|
| Hepacivirus | 1 | 2016 | 421 | 0.110 |
Why?
|
| Neutropenia | 1 | 2018 | 1001 | 0.110 |
Why?
|
| Patient Selection | 1 | 2021 | 2040 | 0.110 |
Why?
|
| Benzamides | 1 | 2019 | 1883 | 0.110 |
Why?
|
| Lymph Nodes | 1 | 2004 | 3067 | 0.110 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2018 | 408 | 0.110 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2003 | 1734 | 0.110 |
Why?
|
| Ipilimumab | 1 | 2018 | 758 | 0.110 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2018 | 630 | 0.110 |
Why?
|
| Middle Aged | 11 | 2018 | 90004 | 0.110 |
Why?
|
| Neoplasm Metastasis | 2 | 2020 | 5324 | 0.100 |
Why?
|
| Risk Assessment | 2 | 2021 | 6829 | 0.100 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2015 | 266 | 0.100 |
Why?
|
| Pyridines | 1 | 2019 | 1311 | 0.100 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2015 | 267 | 0.100 |
Why?
|
| Hepatitis C | 1 | 2016 | 549 | 0.090 |
Why?
|
| Practice Guidelines as Topic | 1 | 2021 | 2421 | 0.090 |
Why?
|
| Dietary Supplements | 1 | 2015 | 566 | 0.090 |
Why?
|
| Pipecolic Acids | 1 | 2010 | 10 | 0.090 |
Why?
|
| Receptor, ErbB-2 | 1 | 2020 | 2648 | 0.090 |
Why?
|
| Hirudins | 1 | 2010 | 41 | 0.090 |
Why?
|
| Antithrombins | 1 | 2010 | 62 | 0.090 |
Why?
|
| Sex Factors | 1 | 2015 | 2189 | 0.080 |
Why?
|
| Hematologic Neoplasms | 1 | 2021 | 1955 | 0.080 |
Why?
|
| Antiviral Agents | 1 | 2016 | 1251 | 0.080 |
Why?
|
| Leukemia | 1 | 2018 | 1720 | 0.080 |
Why?
|
| Biomarkers | 1 | 2019 | 5104 | 0.080 |
Why?
|
| Adult | 8 | 2017 | 81523 | 0.070 |
Why?
|
| Primary Myelofibrosis | 1 | 2015 | 902 | 0.070 |
Why?
|
| Arginine | 1 | 2010 | 509 | 0.070 |
Why?
|
| Endocarditis | 1 | 2008 | 128 | 0.070 |
Why?
|
| Survival Rate | 1 | 2020 | 12516 | 0.070 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2018 | 3393 | 0.070 |
Why?
|
| Treatment Outcome | 3 | 2018 | 33785 | 0.060 |
Why?
|
| Drug Administration Schedule | 1 | 2011 | 3538 | 0.060 |
Why?
|
| Aged | 7 | 2018 | 73156 | 0.060 |
Why?
|
| Urine | 1 | 2004 | 142 | 0.060 |
Why?
|
| Recombinant Proteins | 1 | 2010 | 3073 | 0.060 |
Why?
|
| Urinalysis | 1 | 2004 | 86 | 0.060 |
Why?
|
| Immunotherapy | 1 | 2018 | 3532 | 0.060 |
Why?
|
| Algorithms | 1 | 2015 | 3906 | 0.060 |
Why?
|
| Acute Disease | 2 | 2018 | 2513 | 0.050 |
Why?
|
| Animals | 3 | 2018 | 62754 | 0.050 |
Why?
|
| Cervical Vertebrae | 1 | 2004 | 219 | 0.050 |
Why?
|
| Neoplasms, Second Primary | 1 | 2011 | 1379 | 0.050 |
Why?
|
| Retrospective Studies | 6 | 2022 | 39670 | 0.050 |
Why?
|
| Time Factors | 2 | 2010 | 13102 | 0.050 |
Why?
|
| Fatal Outcome | 1 | 2003 | 837 | 0.050 |
Why?
|
| Sulfonamides | 1 | 2010 | 1919 | 0.050 |
Why?
|
| Melanoma | 1 | 2018 | 5523 | 0.050 |
Why?
|
| Catheters | 1 | 2021 | 134 | 0.040 |
Why?
|
| Urinary Tract Infections | 1 | 2004 | 340 | 0.040 |
Why?
|
| Pregnancy | 1 | 2013 | 8044 | 0.040 |
Why?
|
| Prostate-Specific Antigen | 1 | 2004 | 1037 | 0.040 |
Why?
|
| Biopsy, Needle | 1 | 2004 | 1400 | 0.040 |
Why?
|
| Respiratory Paralysis | 1 | 1999 | 9 | 0.040 |
Why?
|
| Phrenic Nerve | 1 | 1999 | 21 | 0.040 |
Why?
|
| Ventilator Weaning | 1 | 1999 | 33 | 0.040 |
Why?
|
| Aged, 80 and over | 2 | 2017 | 30941 | 0.040 |
Why?
|
| Immunophenotyping | 1 | 2003 | 1730 | 0.040 |
Why?
|
| Prostatectomy | 1 | 2004 | 1005 | 0.040 |
Why?
|
| Adolescent | 3 | 2017 | 32515 | 0.040 |
Why?
|
| Nutrition Therapy | 1 | 2018 | 22 | 0.040 |
Why?
|
| Child | 3 | 2017 | 30328 | 0.040 |
Why?
|
| Electric Stimulation Therapy | 1 | 1999 | 132 | 0.040 |
Why?
|
| Molecular Probe Techniques | 1 | 2017 | 47 | 0.040 |
Why?
|
| Rehabilitation Centers | 1 | 2017 | 73 | 0.040 |
Why?
|
| Celiac Disease | 1 | 2018 | 80 | 0.040 |
Why?
|
| Zinc | 1 | 2018 | 197 | 0.040 |
Why?
|
| Gastric Bypass | 1 | 2018 | 92 | 0.040 |
Why?
|
| Biological Transport | 1 | 2018 | 647 | 0.040 |
Why?
|
| Vitamin K | 1 | 2017 | 55 | 0.030 |
Why?
|
| Lymphoma, Follicular | 1 | 2002 | 636 | 0.030 |
Why?
|
| Tertiary Healthcare | 1 | 2016 | 45 | 0.030 |
Why?
|
| Neck | 1 | 1999 | 386 | 0.030 |
Why?
|
| Disability Evaluation | 1 | 2017 | 243 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2004 | 3972 | 0.030 |
Why?
|
| Adenosine Triphosphatases | 1 | 2018 | 428 | 0.030 |
Why?
|
| Respiration, Artificial | 1 | 1999 | 583 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 2004 | 4967 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2017 | 1538 | 0.030 |
Why?
|
| ROC Curve | 1 | 2017 | 1221 | 0.030 |
Why?
|
| CTLA-4 Antigen | 1 | 2018 | 667 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2004 | 7808 | 0.030 |
Why?
|
| Recurrence | 1 | 2021 | 4879 | 0.030 |
Why?
|
| Inpatients | 1 | 2017 | 691 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2004 | 9040 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2008 | 7782 | 0.020 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2018 | 1088 | 0.020 |
Why?
|
| Length of Stay | 1 | 2017 | 2010 | 0.020 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2002 | 2474 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2017 | 5184 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2004 | 13976 | 0.020 |
Why?
|
| Hospitalization | 1 | 2017 | 2195 | 0.020 |
Why?
|
| Bone Marrow | 1 | 2015 | 2434 | 0.020 |
Why?
|
| Prognosis | 1 | 2004 | 22452 | 0.020 |
Why?
|
| Urinary Bladder, Neurogenic | 1 | 2004 | 52 | 0.010 |
Why?
|
| Urinary Catheterization | 1 | 2004 | 134 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2021 | 10349 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2017 | 16907 | 0.010 |
Why?
|
| Brain Neoplasms | 1 | 2016 | 4982 | 0.010 |
Why?
|
| Young Adult | 1 | 2017 | 22044 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 2004 | 3172 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2008 | 7921 | 0.010 |
Why?
|